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Summary
Background: Comparison of accelerated radiochemotherapy (aRCT)
and standard radiotherapy (sRT) in postoperative treatment after
macroscopically complete resection of squamous cell cancers of
head and neck. Material and Methods: 229 patients treated within
the same period had either (no randomization) postoperative radio-
therapy with conventional fractionation (60–70 Gy, 2.0 Gy per day) or
received 2 fractions of 2.1 Gy per day, 8 times/week, up to a total dose
of 56.7 Gy with a treatment split after 2 weeks and simultaneous low
dose cisplatin or carboplatin on treatment days (cumulative dose
> 66 mg/m2 or 550 mg/m2 in 83% of patients). Results: 65 patients
completed their course of twice-daily irradiations within a maximum
of 35 days and therefore had aRCT; their 3-year locoregional tumor
control (Kaplan-Meier estimate) was 86%, whereas that of 42 pa-
tients with prolonged twice-daily radiochemotherapy was 65%
(p = 0.0509). After sRT, i.e. 1 fraction daily and treatment time up to
45 days, locoregional tumor control was 67%, this result being sig-
nificantly inferior to that after aRCT (p = 0.0282). In multivariate anal-
ysis, pN stage, tumor site oral cavity/floor of mouth, high/moderate
differentiation of squamous cell carcinoma and conventional surgery
(versus CO2-laser surgery) were significantly predictive of locore-
gional failure. Whereas nodal status, the strongest prognostic factor,
was evenly distributed among aRCT and sRT patients, there was 
a misbalance of 3 risk factors favoring the aRCT collective. Superior
tumor control after aRCT was confirmed unilaterally for nearly 
each subgroup (significant for recurrent tumors, close margins,
pN1/2a-b). For pN2c/pN3 nodal stage, the results after aRCT were by
tendency worse than after sRT, possibly due to a particularly long
interval between surgery and start of radio(chemo)therapy for the
patients with aRCT (mean 58.0 days vs. 43.8 days, p = 0.037). Among
the total of patients the 3-year hazard for late toxicity III–IV was 31%
after twice-daily treatment and 17% after conventionally fractionated
radiotherapy (p = 0.083). Conclusions: This retrospective analysis
provides some evidence that accelerated radiotherapy with simul-
taneous chemotherapy is more potent than standard radiotherapy.
However, as multivariate analysis misses significance and the in-
fluence of misbalance of some prognostic factors among aRCT and
sRT patients remains unclear, only a randomized trial with stratifica-
tion according to risk factors as well as a defined interval between
surgery and initiation of RT can provide more evidence.
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Zusammenfassung
Hintergrund: Vergleich von akzelerierter Radiochemotherapie (aRCT)
und Standard-Radiotherapie (sRT) postoperativ nach makroskopisch
kompletter Resektion von Plattenepithelkarzinomen des Kopf-Hals-
Bereichs. Material und Methoden: 229 Patienten wurden im gleichen
Zeitraum therapiert und erhielten entweder (keine Randomisierung)
eine postoperative Radiotherapie (N =122) in konventioneller Frak-
tionierung (60–70 Gy; 2,0 Gy täglich) oder wurden zweimal täglich
(N =107) mit je 2,1 Gy (8 Fraktionen/Woche) bis 56,7 Gy mit Behand-
lungspause nach 2 Wochen und simultan mit niedrig dosiertem Cis-
platin (6 mg/m2 KOF) oder Carboplatin (50 mg/m2), kumulative Dosis
> 66 mg/m2 bzw. 550 mg/m2 bei 83% der Patienten, behandelt.
Ergebnisse: 65 Patienten beendeten die zweimal tägliche Radio-
chemotherapie innerhalb von 35 Tagen und erhielten damit aRCT;
ihre lokoregionäre 3-Jahres-Tumorfreiheit (nach Kaplan-Meier)
betrug 86%, während die von 42 Patienten, deren zweimal tägliche
Bestrahlung sich über einen längeren Zeitraum hinzog, 65% betrug
(p = 0,0509). Nach sRT, definiert als einmal tägliche Bestrahlung und
Behandlungszeit bis 45 Tagen, war die lokoregionäre 3-Jahres-
Tumorfreiheit 67%. Dies ist signifikant schlechter (p = 0,0282) als
nach aRCT. In der multivariaten Analyse erwies sich das pN-Stadium,
Tumorlokalisation in Mundhöhle bzw. -boden, G1- und G2-Differen-
zierung und konventionelle Chirurgie (im Gegensatz zu Laseropera-
tion) als signifikant ungünstig für die lokoregionäre Tumorfreiheit.
Während die pN-Stadien als wichtigster Prognosefaktor gleich ver-
teilt waren unter den sRT- und aRCT-Patienten, begünstigten 3 andere
Risikofaktoren das aRCT-Kollektiv. Im univariaten Vergleich zwischen
Untergruppen wurde eine bessere lokoregionäre Kontrolle nach
aRCT fast immer bestätigt (signifikant für Untergruppen Rezidivbe-
handlung, knappe Resektionsränder, pN1/2a+b). Beim ungünstigen
pN2c/3-Stadium war die lokoregionäre Kontrolle tendenziell schlech-
ter nach aRCT, wobei unter diesen Patienten das Intervall zwischen
Operation und Bestrahlungsbeginn besonders lang war (im Mittel 
58 Tage vs. 44 Tage bei sRT). Das Risiko, innerhalb von 3 Jahren eine
Grad III–IV Toxizität zu entwickeln, betrug nach zweimal täglicher
Bestrahlung 31% und nach konventioneller Fraktionierung 17%
(p = 0,083). Schlußfolgerungen: Diese retrospektive Analyse liefert
Hinweise, daß postoperativ eine akzelerierte Radiotherapie mit
simultaner Chemotherapie wirksamer ist als die Standard-Radio-
therapie. Allerdings erreicht die Bestrahlungsmethode in der multi-
variaten Analyse keine Signifikanz als prognostischer Faktor. Ferner
ist der Einfluß dreier nicht gleich verteilter Prognosefaktoren in den
Kollektiven schwer abschätzbar. Weitere Klärung brächte eine rando-
misierte Studie, die Risikofaktoren gleich gewichtet und ein Intervall
zwischen Operation und Radiotherapie definiert.
Onkologie 2000;23:48–53ONKOLOGIE
Postoperative Irradiation for Squamous Cell Carcinoma of
Head and Neck: Retrospective Comparison of Accelerated
Radiochemotherapy and Standard Radiotherapy
M. Panzera M. Buscha Z. Kiszela M. Schaffera R. Klaibera R. Jundb W. Winterc
E. Kastenbauerb E. Dühmkea
a Klinik für Strahlentherapie und Radioonkologie, 
b Klinik für Hals-Nasen-Ohren-Kranke, 
c Klinik für Mund-Kiefer-Chirurgie, Ludwig-Maximilians-Universität, München
© 2000 S. Karger GmbH, Freiburg
Fax +49 761 4 52 0714 Accessible online at:
E-mail Information@Karger.de www.karger.com/journals/onk
www.karger.com
Dr. Monika Panzer
Klinik für Strahlentherapie und Radioonkologie
Klinikum Großhadern
D-81377 München (Germany)
Tel. +49 89 70 95-37 70, Fax -38 45
Postoperative Accelerated Radiochemotherapy 49Onkologie 2000;23:48–53
Introduction
Postoperative radiotherapy (RT) after surgical resection of
squamous cell carcinomas of the head and neck is performed
with the intention to eradicate residual disease at the former
tumor site and the cervical lymphatic pathways. After com-
bined treatment, earlier retrospective studies [1–4] found a
risk of locoregional failure of 15–45% which varies in relation
to risk factors such as histologic type and extension of nodal
disease, resection margins, oral cavity as primary tumor site,
etc. The randomized study of Peters et al. [5] compared dose
levels of 52.2–54, 57.6, 63, and 68.4 Gy (daily fractions of
1.8 Gy) and established a higher risk of recurrence after doses
less than 54 Gy. Dose escalation above 63 Gy did not improve
the therapeutic ratio. In order to improve the results especially
of high-risk patients, other modes of treatment intensification
have to be tested. Simultaneous chemotherapy with mitomycin
C [6] or cisplatin [7] resulted in significantly better locore-
gional control. Recent considerations on tumor biology focus 
on the time factor [8]. The maximal tumor cell reduction, as
achieved by surgery, is hypothesized to be a potent stimulus 
for tumor cell repopulation. Thus, the postoperative setting
appears to be characterized by accelerated tumor repopulation
and an adequate answer could be an accelerated fractionation
scheme as well as an early initiation of RT.A small randomized
study [9] found no overall benefit for accelerated postopera-
tive RT, however, an advantage for tumors with a high
[3H]thymidine labeling index, i.e. for fast growing tumors.
Preliminary data from an ongoing trial at M.D.Anderson C.C.,
comparing 63 Gy/1.8 Gy per day with 63 Gy given as a con-
comitant boost protocol, reveals a benefit for the accelerated
treatment as well as for a short-time interval between surgery
and the start of RT [10].
This retrospective study compares the results of accelerated
radio(chemo)therapy (aRCT) with those of standard radio-
therapy (sRT) in patients treated postoperatively at the same
institution during the same period.
Materials and Methods
Patients and Radio(chemo)therapy
From 1993 through 1996, 229 patients received RT after macroscopically
complete resection of advanced tumors of oral cavity/floor of mouth,
oropharynx, larynx, and hypopharynx. 50% of the pT1–2 tumors and 34%
of pT3–4 tumors were operated on by CO2-laser technique using operation
microscope. Conventional surgery was significantly more often (chi-square
test p = 0.011) performed in advanced tumor stages (66% of pT3–4 tumors;
50% of pT1–2 tumors).
122 patients were treated with once-daily irradiation with a daily dose of
2.0 Gy 5 times per week by opposing fields (lower neck by anterior field,
50 Gy in 3 cm tissue depth).104 patients (85%) received 60 Gy (or 59.8 Gy)
and 18 patients (15%) 62–70 Gy within the opposing fields.The spinal cord
was excluded after 36 Gy. 72 of 122 patients finished RT within 45 days and
less. This subgroup is addressed as standard radiotherapy (sRT), longer
treatment time is addressed as prolonged RT.
107 patients received 2 fractions of 2.1 Gy per day in midline with a time
interval of 6 hours by the same irradiation techniques. Irradiation was
given on 4 days per week (omitting Wednesdays) with a treatment split of
7–14 days after 2 weeks up to a total dose of 56.7 Gy. First, it was supposed
that a 2-week break is needed for complete resolution of acute mucositis,
but under optimal supportive measures mucositis healed more quickly 
in many patients and the therapy-free interval was routinely shortened to
1 week, resulting in an accelerated course of radiochemotherapy (aRCT)
in 65 of 107 patients, i.e. 56.7 Gy or 64.7 Gy within 35 days or less.The other
patients are addressed as twice-daily RCT without acceleration. On treat-
ment days,most patients received simultaneous cisplatin at a dose of 6 mg/m2
body surface (57 patients with cumulative dose > 66 mg) or carboplatin 
at a dose of 50 mg/m2 body surface (22 patients with cumulative dose
> 550 mg). Chemotherapy was infused over 20–30 min immediately before
the first RT fraction in the morning. It was withheld in patients with com-
promised hearing and renal function, with frailness, multimorbidity, sub-
normal leuko- and thrombocyte counts and those who refused consent.
The decision in favor of one of the RT methods was at the discretion of 
the attending physician responsible for the patient (no randomization).
In the course of the observed period, more patients were submitted to
accelerated treatment because it was felt that this treatment was more
effective. As further analysis will focus on the subgroup of patients receiv-
ing sRT (N = 72) and aRCT (N = 65) the distribution of significantly un-
favorable factors in both subgroups is given in table 1. There is a balance
for nodal status (as well as for other, not significantly influential factors as
gender, primary versus secondary treatment, T stage, resection margins).
The adverse factors G1–2 grading, oral cavity/floor of mouth tumors and
conventional surgery were significantly more prevalent among the sRT
patients. On the other hand, aRCT patients had a significantly longer
interval between surgery and start of RT (p = 0.000).
Follow-up data was collected from the records of the Radiooncology
or/and the Department for Ear, Nose and Throat Diseases. Patients who
did not continue the posttherapeutic control program at our institution
were contacted and information were obtained from their private specia-
lists. In this retrospective analysis, dead patients without documentation of
Table 1. Distribution of prognostic factors among patients with standard
radiotherapy and patients with accelerated radiochemotherapy
Prognostic factor Patients with p Value______________________________________
(unfavorable factors standard accelerated radio-
mentioned first) radiotherapya chemotherapyb______________ __________________
n % n %
pN stage
pN2c/3 17 24 12 18 0.547c
pN1/2a/2b 36 50 35 54
pN0 19 26 18 28
Grading
G1–2 34 47 19 29 0.031c
G3 38 53 46 71
Tumor site
Oral cavity/floor of mouth 32 44 15 23 0.009c
Other localisations 40 56 50 77
Type of surgery
Conventional surgery 49 68 32 48 0.025c
Laser surgery 23 32 33 52
mean range mean range
Time (days) from surgery 40.17 18–112 49.68 24–277 0.000d
to radio(chemo)therapy
a N = 72.
b N = 65.
c Pearson chi-square test.
d t Test for equality of means.
complications or patients alive with extensive local tumor recurrence were
excluded (50 of 229 patients) from the evaluation of chronic side effects.
Planned laryngectomy was not evaluated as a side effect, whereas the
impossibility of regaining larynx function after temporary tracheostomy
was addressed as complication.
Follow-up was calculated from the first day of RT. Actuarial survival and
tumor control was estimated by the Kaplan-Meier method. All statistics
were computed with the help of SPSS statistics software, version 7.5; the
standard error (SE) is indicated in brackets. Survival functions were com-
pared by applying the log-rank test. Prognostic factors (univariate and
multivariate) were determined by a time-constant Cox regression model
using the forced-entry method and the forward stepwise selection. When
both methods yielded the same results, only the data of the forced-entry
method is mentioned. It is indicated, if only the forward stepwise selection
method yielded significant results.The cut-off value for significance was set
at p = 0.05 for all procedures. Prevalence of risk factors in the two treat-
ment groups were calculated by cross-tabs, performing the Pearson chi-
square test. Means were compared by t test for equality of means for
independent samples.
Results
Survival
Among all observed patients (N = 229), the estimate for 3-year
overall survival was 65% (SE 5.3%) for all twice-daily irra-
diated patients and 53% (SE 4.8%) for all once-daily treated
patients (log-rank test p = 0.1751). By comparing the subgroups
of patients with short treatment time (aRCT vs. sRT) there was
a trend for better survival (fig. 1b) after accelerated treatment,
but the difference was not significant (p = 0.097).
Locoregional Control
For the 107 patients treated by twice-daily treatment, the
actuarial 3-year locoregional tumor control (control above
clavicles) is 76% (SE 4.6%), for those 122 patients receiving
once-daily RT, it amounts to 64% (SE 4.8%). The difference is
not significant (log-rank test, p = 0.1207). Among all patients
(N = 229), multivariate Cox regression analysis for indepen-
dent prognostic factors was performed in 2 steps (table 2).
First, potential tumor- and patient-related variables were
screened. The pathological nodal stage emerged as the most
powerful prognostic factor. In a second step, treatment-related
variables were tested. Here, the only significant factor was type
of surgery. Duration of RT, i.e. sRT or aRCT versus prolonged
or not accelerated treatment, failed to reach significance
(p = 0.1278).
In univariate analysis, patients with aRCT (N = 65) had a sig-
nificantly better 3-year locoregional control than those with
RCT without acceleration (N = 42) (log-rank test, p = 0.051).
There was, however, no difference as to locoregional control
between patients with sRT (N = 72) and patients with pro-
longed RT (N = 50; p = 0.804). Therefore, in order to evaluate
the effect of accelerated RCT, further analysis compares the
subgroups of patients treated with aRCT and sRT, leaving
aside the patients with longer treatment time: Multivariate Cox
regression analysis of tumor-related variables revealed the
same prognostic factors among the subgroup of 137 patients as
the analysis for the total of patients shown in table 2. However,
Cox regression analysis for treatment-related variables could
not isolate a significant factor, type of surgery being again the
strongest factor (p = 0.0834). In bilateral comparison, aRCT
results in significantly better 3-year locoregional tumor control
than sRT (p = 0.0282; fig. 1a), which was confirmed by uni-
variate Cox regression analysis (p = 0.0278). Most subgroups
defined by risk factors profited from aRT (significantly or by
tendency) with the exception (by tendency) of high pN stage
and R1 resection (table 3). Among the 65 patients receiving
aRCT, 3-year locoregional tumor control was 85% (SE 5.6%)
for those with simultaneous cisplatin, 100% for those with
carboplatin (N = 3) and 83% (SE 8.8%) for those without
chemotherapy or low cumulative doses (p = 0.701). Univariate
Cox regression analysis revealed no significant influence of
interval between surgery and irradiation both in the aRCT
group (p = 0.496) and the sRT group (p = 0.4738).
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Fig. 1. Actuarial (Kaplan-Meier estimate) locoregional control (a) and overall survival (b) of patients receiving either postoperative accelerated radio-
chemotherapy (
nn
; N = 65) or standard radiotherapy (
n
; N = 78). 3-year locoregional tumor control is 86 and 67%, the difference is significant (p = 0.0282
in log-rank test). 3-year overall survival is 71 and 47% (p = 0.097 in log-rank test).
Distant Metastasis
Multivariate Cox regression analysis identified pN stage
(p = 0.0001), hypopharynx as tumor site (p = 0.0021) and
pN0/pN+ without extracapsular nodal disease versus pN+ with
extranodal disease (p = 0.0287) as significant predictors for
distant metastasis. After aRCT, 3-year freedom from distant
metastasis was 84% (SE 5.0%) and 75% (SE 5.9%) after sRT;
the difference is not significant.
Complications
Complications were evaluated for all patients. Acute mucositis
RTOG II–III was encountered in all observed patients. Those
receiving twice-daily irradiations usually experienced a peak
mucosal reaction during the treatment split and again at the
end of RCT. Those getting standard treatment had maximal
mucositis during the last 2–3 weeks of therapy. Acute muco-
sitis RTOG IV was documented (no standardized records) for
3 of 107 patients receiving twice-daily RCT.With intensive sup-
port (antibacterial and antimycotic) the therapy-free interval
could be shortened without giving up the principle that muco-
sitis should be healed (allowing receding mucositis RTOG I)
before continuing treatment.
The hazard to develop grade III–IV complications was 17%
(SE 4.0%) for the once-daily irradiated patients and 31% (SE
4.8%) for the twice-daily treated patients, the difference not
being significant (log-rank test, p = 0.1232). The difference for
grade IV toxicity was more pronounced (hazard 4%, SE 2.2%
vs. 14%, SE 3.6%), but still not significant (log-rank test,
p = 0.0834).
More hematologic toxicity was encountered in 22 patients
receiving carboplatin 50 mg/m2 body surface on treatment days
than in 65 patients treated with 6 mg/m2 cisplatin (Leukopenia:
CTC grade 3 after carboplatin 4/22 patients, after cisplatin 1/65;
CTC grade 4 after carboplatin 1/22; Thrombocytopenia: CTC
grade 3 after carboplatin 6/22 patients, after cisplatin 2/65, CTC
grade 4 after carboplatin 2/22 patients; elevation of serum urea
(double of normal value) 1/22 after carboplatin, 0/65 after
cisplatin).
Discussion
The results of postoperative twice-daily radiochemotherapy
(split course with therapy-free interval after 2 weeks) were
influenced by overall treatment time. Patients having aRCT
(56.7 Gy or 64.7 Gy within 5 weeks) did significantly better (in
univariate comparison) than those with prolonged treatment
time (p = 0.0509; log-rank test). By comparing postoperative
sRT (60 Gy and more in up to 6.5 weeks) with aRCT, a signifi-
cantly better 3-year locoregional tumor control was found with
accelerated fractionation and simultaneous low-dose chemo-
therapy. This benefit does not yet translate into significantly
better overall survival. Whereas locoregional recurrences
establish themselves early after therapy, a longer time of obser-
vation is required before judging definitively the effect on
overall survival.
These observations confirm the experiences of Amdur [1] who
found significantly worse disease specific and overall survival
for patients receiving postoperative RT in standard fractiona-
tion with treatment split.
No significant influence was found of the interval between
surgery and radiotherapy, which varied widely in this retro-
spective analysis (table 1). Other authors [2, 5] report likewise
about only a tendency for better tumor control if RT is begun
within 6 weeks; in the retrospective analysis of Amdur et al. [1]
the time interval was not prognostically relevant. We observed
better locoregional control within the overall aRCT group,
although the mean interval between surgery and initiation of
RT had been longer there than in the sRT group.
There are, however, two reports providing conflicting results.
These authors [3, 10], both applying accelerated radiotherapy
with concomitant boost regimes to exclusively high-risk pa-
tients, find a significant influence of the time (4 resp. 6 weeks)
between surgery and RT. In our subgroup analysis, the small
group of high-risk patients (pN2c/3, R1-resection) did not
profit from aRCT. The fact that the high-risk patients of the
aRCT collective had been waiting longer for start of adjuvant
treatment (mean 58 days) than those of the sRT group (mean
44 days) might have been adverse, and acceleration or simulta-
neous chemotherapy could not compensate for it. As hypothe-
sized by Peters and Withers [8] and supported by clinical data
from Trotti [3], the interval between surgery and radiotherapy
is characterized by accelerated repopulation. Locoregional
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Table 2. Multivariate analysis (Cox regression) of prognostic factors for
locoregional tumor control among all observed patients (n = 229)
Prognostic factor Rank p Value1
(unfavorable characteristic
mentioned first)
Tumor- and patient-related factors
Pathological N stage (pN2c/3 vs.
pN1/2a/2b vs. pN0) 1 0.0001
Grading (G1–2 vs. G3) 2 0.0026
Tumor site oral cavity/floor of mouth 3 0.0136
Tumor site hypopharynx 4 0.0797
Pathological T-stage (pT4 vs. pT3 vs. pT2 vs. pT1) 5 0.1079
Therapy for recurrent tumor 6 0.1733
Extracapsular nodal disease 7 0.4395
Tumorsite oropharynx 8 0.4841
Patient sex (male vs. female) 9 0.6435
Patient age 10 0.6558
Tumor site larynx 11 0.8612
Treatment-related factors
Type of surgery (conventional surgery vs.
CO2-Laser-Surgery) 1 0.0014
Prolonged time of radiotherapy 2 0.1278
Resection margins 3 0.2008
Type of radiotherapy (one fraction/day vs. two
fractions/day) 4 0.4514
Time between surgery and radiotherapy 5 0.9651
1 Time constant Cox regression analysis.
control in high-risk patients might be more dependant on the
time elapsed since surgery, maybe due to higher tumor load.
Interestingly, high or moderate differentiation of squamous
cell carcinoma appeared as a significant adverse factor. The
ability to accelerated repopulation seems to be more devel-
oped in well and moderately differentiated tumors than in
poorly differentiated ones [11]. Therefore treatment time
should be particularly influential in better differentiated
tumors, affecting G3 tumors less. Although G3 tumors were
prevailing among the twice-daily irradiated patients, locore-
gional control was significantly dependent on treatment time.
Our regimen is a split-course regimen and long treatment
interruptions might be detrimental even to G3 tumors. In
subgroup comparison between aRCT and sRT, we found a
nonsignificant trend for better locoregional control after
aRCT both for G1/2 and G3 tumors. Again, this observation
does not appear to be consistent with a different ability for
accelerated repopulation in G2 and G3 tumors. However, the
differences did not reach significance and other factors might
have also influenced the results.
Our data reconfirms earlier observations which find tumor
features to be strong prognostic factors in postoperative RT.
The aRCT and sRT collectives differ in the distribution of risk
factors (table 1) with a preponderance of three unfavorable
factors in the sRT group, but a balance as to the most influen-
tial factor, which was nodal stage.
The data do not allow us to analyze the effect of simultaneous
low-dose chemotherapy. More toxicity was encountered after
carboplatin than after cisplatin, maybe due to a relatively
higher dosage. Other authors [12] applied also 6 mg/m2 cis-
platin 5 times per week up to a cumulative dose of 270 mg/m2
versus carboplatin 25 mg/m2, which is half of dose applied by
us, and found an equivalent effect in simultaneous radioche-
motherapy for inoperable head and neck tumors. Their third
treatment arm consisted of RT alone and resulted in signifi-
cantly worse locoregional control. In postoperative therapy
Bachaud [7] found a significant benefit for simultaneous
cisplatin given once per week up to a cumulative dose of
350–450 mg absolute.
For patients with high nodal stage, the risk to develop distant
metastasis was impressively high (60% after 4 years for pN2c
and pN3). Tumor site hypopharynx and extracapsular exten-
sion of nodal disease were also predictive of distant metastasis.
Whereas the recurrence pattern after primary radio(chemo)-
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Subgroup by risk factor Locoregional control p Value
in patients with______________________________________________________
standard radiotherapy accelerated radio-
(N = 72) chemotherapy (N = 65)________________________ _________________________
% SE % SE
pN stage
pN0 74 10 94 5 n.s.
pN1/2a/2b 63 9 94 4 0.0091
pN2c/3a 68 12 49 15 n.s.
Resections margins
R0 71 11 83 11 n.s.
Close margins 58 9 91 5 0.0006
R1b 75 11 71 12 n.s.
Grading
G1–2 55 9 72 10 n.s.
G3 78 7 91 4 n.s.
Tumor site
Oral cavity/floor of mouth 57 9 73 12 n.s.
No extension to oral 75 8 89 5 n.s.
Cavity/floor of mouth
Timing of treatment
Primary therapy 70 6 83 6 n.s.
Therapy for recurrent 54 12 94 6 0.0182
Tumor after surgery alone
a In this subgroup the mean intervall between surgery and radiotherapy was 43.8 days for patients
with standard treatment and 58.0 days for patients with accelerated treatment (t test; p value 0.037).
b In this subgroup the mean interval between surgery and radiotherapy was 42.5 days for patients
with standard treatment and 46.9 days for patients with accelerated treatment ( t test; p value 0.518).
Table 3. Patients with short treatment 
time (n =142): Subgroup analysis of actuarial 
locoregional 3-year control (Kaplan-Meier-
estimate)
therapy for inoperable head and neck tumors is dominated by
locoregional failures [13], at least within this subgroup of pa-
tients, distant metastases became a frequent cause of death.
The efficacy of adjuvant chemotherapy to prevent distant
metastasis in combination with postoperative RT is not
established yet [14, 15] and currently tested in a German multi-
center trial (ARO-96-3).
Severe chronic toxicity was more often encountered after
twice-daily RCT than after once-daily RT (difference not
significant), although most patients received a lower total dose
than with standard fractionation. Other trials applying acceler-
ated fractionation for head and neck tumors found signifi-
cantly worse toxicity [overview 8] than after standard frac-
tionation or hyperfractionation.We gave twice-daily single doses
of 2.1 Gy in midline 8 fractions per week (weekly dose 16.8 Gy)
according to a previously developed protocol [16]. As the reac-
tion of late responding tissues is related to the size of dose per
fraction, decreasing single dose to 1.8 Gy (9 fractions 
per week), as meanwhile implemented, might reduce late
complications.
The retrospective data presented seems to support the hypo-
thesis that postoperative aRCT results in better locoregional
control. However, multivariate analysis misses significance and
the influence of misbalance of prognostic factors among aRCT
and sRT patients remains unclear. Further evidence must be
expected from a randomized trial with stratification according
to risk factors as well as a constant interval between surgery
and initiation of RT.
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